• Immunome director Isaac Barchas disclosed sales of 201,050 common shares on June 30 and July 2.
• Shares sold at weighted average prices of $21.12, $22.35, $23.33.
• Indirect holdings reported at 208,504 shares following the transactions.
• Direct holdings reported at 103,259 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunome Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001808343-26-000005), on July 02, 2026, and is solely responsible for the information contained therein.